Additional Information
Dr. Philbin will discuss current research on long-acting injectable antiretroviral therapy (ART) and HIV pre-exposure prophylaxis (PrEP) with a focus on the multilevel barriers and facilitators to successful implementation. She will also highlight key points that must be addressed to scale up biomedical HIV technologies—in ways that maximize population health impact and reduce existing disparities—related to current formulations of PrEP and ART. Dr. Philbin’s research has been funded by several NIH Institutes, including the National Institute on Drug Abuse, the National Institute on Minority Health and Health Disparities (NIMHD), the National Institute of Allergy and Infectious Diseases, and the National Institute of Mental Health.
More about this and other lectures in the series can be found at https://prevention.nih.gov/news-events/early-stage-investigator-lecture/2021-awardees